

Anti-DLL4 & VEGF Reference Antibody (Navicixizumab)

Catalog # APR11608

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9NR61 & P15692
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information


Target/Specificity	DLL4, VEGF
Expression system	CHO

Protein Information

Images




Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.





The purity of Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) is 97.99%, determined by SEC-HPLC.


Navicixizumab bound to DLL4 protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Navicixizumab bound to huDLL4-His, and the EC50 was 0.033 nM.




Navicixizumab bound to VEGFA protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Navicixizumab bound to huVEGFA-His, and the EC50 was 0.020 nM.



Navicixizumab bound to huDLL4-FL-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Navicixizumab bound to huDLL4-FL-HEK293 cells, and the EC50 was 4.603 nM.



To evaluate the neutralizing activity of Navicixizumab against VEGF. Co-incubation of Navicixizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Navicixizumab can neutralize VEGF-165, and the IC50 was 7.957 nM.



The detected molecular weight of Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) is 145.91 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.